HAMBURG, GERMANY, AND TORONTO, ON / ACCESSWIRE / April 2, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the innovative biotechnology company panCELLa Inc.

About Fate Therapeutics’ iPSC Product PlatformThe Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell ...

The MarketWatch News Department was not involved in the creation of this content. SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pluristyx, Inc., a leading biotechnology company specializing in tools and ...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic, a cell therapy platform provider that partners with therapeutic developers to ensure cell therapies can achieve their full potential, has ...

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) ...

This data represents a step forward in developing next-generation ‘off-the-shelf’ iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential ...

SEATTLE--(BUSINESS WIRE)--Curi Bio, a leading developer of human iPSC-based platforms for drug discovery, today announced the ComboMat™ platform, a proprietary human iPSC-derived cardiomyocyte ...

The Emulate Brain-Chip R1 integrates key FUJIFILM Cellular Dynamics iCell (R) products co-cultured with Emulate's proprietary induced Brain Microvascular Endothelial Cells (BMECs) to provide ...

iXCells’ cell engineering platform iPSCore ™ is a unified and dedicated system where tools, skills, experiences and expertise are structured together to design, develop and build iPSC-derived cell ...

SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pluristyx, Inc., a leading biotechnology company specializing in tools and technologies for the development of induced pluripotent stem cell (iPSC)-based ...